Capstone Therapeutics Corp.

CAPS Basic Materials Building Materials

Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.

0.09 0.01 −10.00%
Market cap
$2.7M
P/E
0.0×
Fwd P/E
5.3×
Dividend yield
—
F-score
3/9
Altman Z
−5.67
Beneish M
−3.81
Dividend safety
n/a

Capstone Therapeutics Corp. (CAPS) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Capstone Therapeutics Corp. (CAPS) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from 0.0× (September 2024) to 0.7× (April 2025); the current reading is higher than 87% of that period. That is below the Building Materials industry median of 1.9× and below the Basic Materials sector median of 1.7×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 0.6× 71.79%
FY2024 0.3× —
FY2023 0.0× —
FY2018 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 0.5× (23.27%)
Mar 2026 0.6× 8.57%
Dec 2025 0.6× (2.57%)
Sep 2025 0.6× (3.49%)
7 more quarters

Against its own ten years

Low 0.0× High 0.7×
Ten-year median 0.0×
Current reading's percentile 87

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CAPS